A few types of high-metastatic cancer cell lines including nasopharyngeal carcinoma, lung cancer, breast cancer, and gastric cancer cell lines were selected for developing in vitro cell models for anti-metastatic drug screening. Based on the cancer cell metastatic mechanisms/pathways such as epithelial-mesenchymal transition (EMT), we selected a metastasis-related molecular marker, called the motility-promoting (Pro-M) gene whose expression level is involved with the motility of cancer cells. Then, we inserted a GFP-Luciferase cassette into the downstream of the Pro-M gene as a reporter. The Pro-M gene is related to the cytoskeleton and has a strong correlation with tumor cell movement. After adding a compound, and detecting the expression of GFP or Luciferase, we can quickly determine whether the compound has the potential to inhibit the movement of tumor cells. The tool cell model can be used for rapid preliminary high-throughput screening of compounds with anti-tumor metastasis activity.
Candidate compounds obtained after screening must be subjected to rigorous in vitro and in vivo verification experiments before they can enter subsequent clinical trials. To date, Exploring Health has completed the screening of four compound libraries, and identified 60 hit compounds that showed the potential inhibition of metastasis. Based on these hit compounds, we have designed more than 100 lead compounds. After further optimization and verification through in vitro and in vivo experiments, we have obtained nearly 20 compounds against cancer cell metastasi. Twelve of the compounds have been authorized patent right by the State Interllectual Property Office of China or are patent-pending.
1. Fast. 24h detection..
2. Efficient. 5000 compounds/48h/batch.
3. Stable and good repeatability.
